CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| NRG-HN003 | NRG | A Phase I and Expansion Cohort Study of Adjuvant Cisplatin; Intensity-Modulated Radiotherapy; and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC) | Adult CIRB - Early Phase Emphasis | Completed |
| NRG-HN004 | NRG | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN005 | NRG | A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN006 | NRG | Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN007 | NRG | An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-HN008 | NRG | Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Adult CIRB - Early Phase Emphasis | Available to Open |
| NRG-HN009 | NRG | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN010 | NRG | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-HN011 | NRG | A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-LU001 | NRG | Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |